Literature DB >> 24490030

High-dose prazosin for the treatment of post-traumatic stress disorder.

Maju Mathew Koola1, Sajoy P Varghese2, Jan A Fawcett3.   

Abstract

Patients with post-traumatic stress disorder (PTSD) are frequently symptomatic despite being on medications currently approved by the US Food and Drug Administration for PTSD. There is evidence to support the notion that prazosin is effective for PTSD nightmares. However, PTSD-related nightmares often do not resolve completely on a low dose of prazosin. The capacity of prazosin to treat daytime symptoms of PTSD which are distressing to patients has not been well studied. Clinicians are reluctant to increase the dose of prazosin due to side effect concerns. To date, the highest reported dose of prazosin used for PTSD is 16 mg daily. We illustrate two case reports using high-dose (up to 30 and 45 mg) prazosin for PTSD with comorbid treatment-resistant mood disorders. We report that high-dose prazosin was safe, tolerable and effective for PTSD in adults. To our knowledge, this is the first case series to highlight the importance of using high-dose prazosin for the treatment of PTSD. In patients with partial response to currently available medications for PTSD, greater utilization of high-dose prazosin for the management of PTSD may lead to better outcomes.

Entities:  

Keywords:  High dose prazosin; comorbid depression; post-traumatic stress disorder

Year:  2014        PMID: 24490030      PMCID: PMC3896131          DOI: 10.1177/2045125313500982

Source DB:  PubMed          Journal:  Ther Adv Psychopharmacol        ISSN: 2045-1253


  14 in total

Review 1.  Pramipexole in psychiatry: a systematic review of the literature.

Authors:  Chris B Aiken
Journal:  J Clin Psychiatry       Date:  2007-08       Impact factor: 4.384

2.  Is monotherapy as good as polypharmacy in long-term treatment of bipolar disorder?

Authors:  Martin Alda; Lakshmi N Yatham
Journal:  Can J Psychiatry       Date:  2009-11       Impact factor: 4.356

Review 3.  When at first you don't succeed: sequential strategies for antidepressant nonresponders.

Authors:  M E Thase; A J Rush
Journal:  J Clin Psychiatry       Date:  1997       Impact factor: 4.384

Review 4.  Treatment of nightmares with prazosin: a systematic review.

Authors:  Simon Kung; Zelde Espinel; Maria I Lapid
Journal:  Mayo Clin Proc       Date:  2012-08-09       Impact factor: 7.616

5.  The PHQ-9: validity of a brief depression severity measure.

Authors:  K Kroenke; R L Spitzer; J B Williams
Journal:  J Gen Intern Med       Date:  2001-09       Impact factor: 5.128

6.  Declining benzodiazepine use in veterans with posttraumatic stress disorder.

Authors:  Brian C Lund; Nancy C Bernardy; Bruce Alexander; Matthew J Friedman
Journal:  J Clin Psychiatry       Date:  2011-11-29       Impact factor: 4.384

Review 7.  The use of antidepressants in bipolar disorder.

Authors:  Virginio Salvi; Andrea Fagiolini; Holly A Swartz; Giuseppe Maina; Ellen Frank
Journal:  J Clin Psychiatry       Date:  2008-08       Impact factor: 4.384

Review 8.  Psychostimulants for depression.

Authors:  M Candy; L Jones; R Williams; A Tookman; M King
Journal:  Cochrane Database Syst Rev       Date:  2008-04-16

9.  A pilot trial of the alpha-1 adrenergic antagonist, prazosin, for alcohol dependence.

Authors:  Tracy L Simpson; Andrew J Saxon; Charles W Meredith; Carol A Malte; Brittney McBride; Laura C Ferguson; Christopher A Gross; Kim L Hart; Murray Raskind
Journal:  Alcohol Clin Exp Res       Date:  2008-10-21       Impact factor: 3.455

10.  Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009.

Authors:  Lakshmi N Yatham; Sidney H Kennedy; Ayal Schaffer; Sagar V Parikh; Serge Beaulieu; Claire O'Donovan; Glenda MacQueen; Roger S McIntyre; Verinder Sharma; Arun Ravindran; L Trevor Young; Allan H Young; Martin Alda; Roumen Milev; Eduard Vieta; Joseph R Calabrese; Michael Berk; Kyooseob Ha; Flávio Kapczinski
Journal:  Bipolar Disord       Date:  2009-05       Impact factor: 6.744

View more
  23 in total

1.  A Case of Electroconvulsive Therapy-Resistant Depression Responding to Multiple Dopaminergic Medications.

Authors:  Maju Mathew Koola; Jan A Fawcett
Journal:  Prim Care Companion CNS Disord       Date:  2015-04-30

2.  Naltrexone and prazosin combination for posttraumatic stress disorder and alcohol use disorder.

Authors:  Hamid Qazi; Heshan Wijegunaratne; Ravi Savajiyani; Maju Mathew Koola
Journal:  Prim Care Companion CNS Disord       Date:  2014-08-21

3.  Fludrocortisone in posttraumatic stress disorder: effective for symptoms and prazosin-induced hypotension.

Authors:  Mansi Vaishnav; Vanessa Patel; Sajoy P Varghese; Jeffrey C McCagh; Maju Mathew Koola
Journal:  Prim Care Companion CNS Disord       Date:  2014-12-04

4.  Noradrenergic α1-Adrenoceptor Actions in the Primate Dorsolateral Prefrontal Cortex.

Authors:  Dibyadeep Datta; Sheng-Tao Yang; Veronica C Galvin; John Solder; Fei Luo; Yury M Morozov; Jon Arellano; Alvaro Duque; Pasko Rakic; Amy F T Arnsten; Min Wang
Journal:  J Neurosci       Date:  2019-02-12       Impact factor: 6.167

Review 5.  Management of Post-Traumatic Nightmares: a Review of Pharmacologic and Nonpharmacologic Treatments Since 2013.

Authors:  Scott H Waltman; David Shearer; Bret A Moore
Journal:  Curr Psychiatry Rep       Date:  2018-10-11       Impact factor: 5.285

Review 6.  The Black Book of Psychotropic Dosing and Monitoring.

Authors:  Alan F Schatzberg; DeBattista Charles
Journal:  Psychopharmacol Bull       Date:  2018-01-15

7.  Noradrenergic blockade stabilizes prefrontal activity and enables fear extinction under stress.

Authors:  Paul J Fitzgerald; Thomas F Giustino; Jocelyn R Seemann; Stephen Maren
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-29       Impact factor: 11.205

8.  Evidence for Using Doxazosin in the Treatment of Posttraumatic Stress Disorder.

Authors:  Cherish Smith; Maju Mathew Koola
Journal:  Psychiatr Ann       Date:  2016-09-12

9.  Perils of Pragmatic Psychiatry: How We Can Do Better.

Authors:  Maju Mathew Koola; Joseph Sebastian
Journal:  HSOA J Psychiatry Depress Anxiety       Date:  2016-02-23

Review 10.  Potential role of the combination of galantamine and memantine to improve cognition in schizophrenia.

Authors:  Maju Mathew Koola; Robert W Buchanan; Anilkumar Pillai; Katherine J Aitchison; Daniel R Weinberger; Scott T Aaronson; Faith B Dickerson
Journal:  Schizophr Res       Date:  2014-05-28       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.